NASDAQ:SCPH scPharmaceuticals (SCPH) Stock Price, News & Analysis → Forget AI, Imperium Is Expected to Grow 320,00% in 3 Years (From Banyan Hill Publishing) (Ad) Free scph Stock Alerts $4.49 +0.14 (+3.22%) (As of 04/26/2024 ET) Add Compare Share Share Today's Range$4.32▼$4.5850-Day Range$4.35▼$6.2252-Week Range$4.25▼$12.75Volume119,733 shsAverage Volume221,799 shsMarket Capitalization$161.86 millionP/E RatioN/ADividend YieldN/APrice Target$19.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get scPharmaceuticals alerts: Email Address scPharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside330.6% Upside$19.33 Price TargetShort InterestBearish13.26% of Shares Sold ShortDividend StrengthN/ASustainability-0.82Upright™ Environmental ScoreNews Sentiment0.00Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.47) to ($0.66) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.19 out of 5 starsMedical Sector321st out of 908 stocksPharmaceutical Preparations Industry141st out of 419 stocks 3.5 Analyst's Opinion Consensus RatingscPharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragescPharmaceuticals has only been the subject of 1 research reports in the past 90 days. Previous Next 0.0 Short Interest Percentage of Shares Shorted13.26% of the outstanding shares of scPharmaceuticals have been sold short.Short Interest Ratio / Days to CoverscPharmaceuticals has a short interest ratio ("days to cover") of 21.6, which indicates bearish sentiment.Change versus previous monthShort interest in scPharmaceuticals has recently increased by 3.46%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldscPharmaceuticals does not currently pay a dividend.Dividend GrowthscPharmaceuticals does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScorescPharmaceuticals has received a 70.52% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " product. See details.Environmental SustainabilityThe Environmental Impact score for scPharmaceuticals is -0.82. Previous Next 0.6 News and Social Media Coverage News Coverage This WeekMarketBeat has tracked 3 news articles for scPharmaceuticals this week, compared to 1 article on an average week.MarketBeat Follows3 people have added scPharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 50% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, scPharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.68% of the stock of scPharmaceuticals is held by insiders.Percentage Held by Institutions89.52% of the stock of scPharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for scPharmaceuticals are expected to grow in the coming year, from ($1.47) to ($0.66) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of scPharmaceuticals is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of scPharmaceuticals is -3.16, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioscPharmaceuticals has a P/B Ratio of 4.32. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Colonial MetalsConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareThe latest flare-up between Israel and Palestinian militants has sent gold prices surging. Why? Because savvy investors know the endgame of the elites at play… Geopolitical crises breed uncertainty — and gold thrives on uncertainty. See why the elites are pouring billions into gold. About scPharmaceuticals Stock (NASDAQ:SCPH)scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. Its lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion due to fluid overload in adults with chronic heart failure and kidney disease, as well as consists of subcutaneous loop diuretic that delivers IV equivalent diuresis at home; and FUROSCIX On-Body Infusor, a drug-device combination product consisting of FUROSCIX. The company's product pipeline also includes SCP-111 (furosemide injection), an investigational pH neutral aqueous furosemide formulation that is being developed for subcutaneous administration outside of the hospital setting, including patient self-administration in the home; and SCP-111 Autoinjector, an investigational single-entity, drug-device combination product candidate consisting of a prefilled syringe containing SCP-111, preloaded into a commercially available, fixed single dose, disposable, two step mechanical autoinjector. It has a collaboration agreement with West Pharmaceutical Services, Inc. The company was incorporated in 2013 and is headquartered in Burlington, Massachusetts.Read More SCPH Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart SCPH Stock News HeadlinesApril 24, 2024 | finance.yahoo.comscPharmaceuticals Inc. (SCPH) Interactive Stock Chart - Yahoo FinanceApril 24, 2024 | markets.businessinsider.comscPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) InjectionApril 27, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.April 24, 2024 | globenewswire.comscPharmaceuticals Announces First Participant Enrolled in Pivotal Pharmacokinetic Study of FUROSCIX Auto-Injector (furosemide 80mg/mL) InjectionApril 10, 2024 | msn.comNovel Biannual Antihypertensive Shows Potential for Combination TherapyMarch 27, 2024 | finance.yahoo.comThose who invested in scPharmaceuticals (NASDAQ:SCPH) five years ago are up 62%March 20, 2024 | finanznachrichten.descPharmaceuticals, Inc.: scPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateMarch 16, 2024 | insidermonkey.comscPharmaceuticals Inc. (NASDAQ:SCPH) Q4 2023 Earnings Call TranscriptApril 27, 2024 | Banyan Hill Publishing (Ad)The Best AI Stock to Own in the World Today is Trading for Just $25“Titan of Tech” Bets Big on Tiny AI Company He’s made as much as 3,250,000% in just three years on companies like Facebook, Airbnb, and PayPal… But our research shows his latest investment could be his most successful venture yet.March 16, 2024 | finance.yahoo.comSCPH Apr 2024 5.000 putMarch 15, 2024 | markets.businessinsider.comBuy Rating Affirmed for scPharmaceuticals Amidst Revenue Surge and Solid Financial FootingMarch 14, 2024 | finance.yahoo.comQ4 2023 scPharmaceuticals Inc Earnings CallMarch 14, 2024 | markets.businessinsider.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Neurocrine (NBIX), Jazz Pharmaceuticals (JAZZ) and scPharmaceuticals (SCPH)March 14, 2024 | markets.businessinsider.comStrong Buy Recommendation for scPharmaceuticals on Furoscix’s Successful Launch and Growth ProspectsMarch 13, 2024 | finance.yahoo.comscPharmaceuticals Inc (SCPH) Reports Q4 and Full-Year 2023 Financials, Focusing on FUROSCIX GrowthMarch 13, 2024 | globenewswire.comscPharmaceuticals Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business UpdateMarch 12, 2024 | msn.comscPharmaceuticals Q4 2023 Earnings PreviewMarch 11, 2024 | markets.businessinsider.comCraig-Hallum Reaffirms Their Buy Rating on scPharmaceuticals (SCPH)March 9, 2024 | markets.businessinsider.comscPharmaceuticals Inc Registered Shs hosts conference call for investorsMarch 6, 2024 | globenewswire.comscPharmaceuticals to Announce Fourth Quarter and Full-Year 2023 Financial Results on Wednesday, March 13, 2024February 28, 2024 | globenewswire.comscPharmaceuticals to Participate in Two Upcoming Investor ConferencesFebruary 21, 2024 | benzinga.comscPharmaceuticals Stock (NASDAQ:SCPH), Short Interest ReportJanuary 15, 2024 | finanznachrichten.deDelveInsight Business Research, LLP: Heart Failure Treatment Drug Market to Accelerate Immensely by 2032, Predicts DelveInsightJanuary 8, 2024 | msn.comTop 10 stocks with the highest short interest on Wall StreetJanuary 7, 2024 | markets.businessinsider.comStrong Buy: scPharmaceuticals’ Furoscix Shows Robust Sales Growth and Solid Financial HealthJanuary 5, 2024 | markets.businessinsider.comBuy Rating for scPharmaceuticals: Furoscix’s Market Traction and Growth Potential Drive Positive ValuationJanuary 5, 2024 | finanznachrichten.descPharmaceuticals, Inc.: scPharmaceuticals Announces Preliminary Unaudited Q4 and Full-Year 2023 Net FUROSCIX RevenueSee More Headlines Receive SCPH Stock News and Ratings via Email Sign-up to receive the latest news and ratings for scPharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/13/2024Today4/27/2024Next Earnings (Estimated)5/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:SCPH CUSIPN/A CIK1604950 Webwww.scpharma.com Phone(617) 517-0730FaxN/AEmployees135Year FoundedN/APrice Target and Rating Average Stock Price Target$19.33 High Stock Price Target$20.00 Low Stock Price Target$18.00 Potential Upside/Downside+330.6%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage2 Analysts Profitability EPS (Most Recent Fiscal Year)($1.42) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,810,000.00 Net Margins-403.22% Pretax Margin-403.22% Return on Equity-97.18% Return on Assets-49.59% Debt Debt-to-Equity Ratio1.04 Current Ratio7.08 Quick Ratio6.40 Sales & Book Value Annual Sales$13.59 million Price / Sales11.91 Cash FlowN/A Price / Cash FlowN/A Book Value$1.04 per share Price / Book4.32Miscellaneous Outstanding Shares36,050,000Free Float34,367,000Market Cap$161.86 million OptionableOptionable Beta0.06 The 10 Best AI Stocks to Own in 2024Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.Get This Free Report Key ExecutivesMr. John H. Tucker (Age 61)President, CEO, Principal Executive Officer & Director Comp: $981.56kMs. Rachael Nokes (Age 48)CFO & Principal Accounting Officer Comp: $573.8kMr. Michael D. HassmanSenior Vice President of Technical OperationsKatherine TaudvinVice President of Corporate Affairs & Human ResourcesDr. John Mohr Pharm.D.Senior Vice President of Clinical Development & Medical AffairsSteve ParsonsSenior Vice President of CommercialMore ExecutivesKey CompetitorsGossamer BioNASDAQ:GOSSProQR TherapeuticsNASDAQ:PRQRGreenwich LifeSciencesNASDAQ:GLSIAEON BiopharmaNASDAQ:AEONTelomir PharmaceuticalsNASDAQ:TELOView All CompetitorsInstitutional OwnershipAssenagon Asset Management S.A.Bought 19,822 shares on 4/24/2024Ownership: 0.055%Rice Hall James & Associates LLCBought 200,101 shares on 4/23/2024Ownership: 0.780%Thomasville National BankBought 3,800 shares on 4/10/2024Ownership: 0.102%Rubric Capital Management LPBought 786,713 shares on 2/14/2024Ownership: 9.760%Tower Research Capital LLC TRC Sold 6,472 shares on 2/13/2024Ownership: 0.015%View All Institutional Transactions SCPH Stock Analysis - Frequently Asked Questions Should I buy or sell scPharmaceuticals stock right now? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for scPharmaceuticals in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" SCPH shares. View SCPH analyst ratings or view top-rated stocks. What is scPharmaceuticals' stock price target for 2024? 2 brokers have issued 12 month price targets for scPharmaceuticals' shares. Their SCPH share price targets range from $18.00 to $20.00. On average, they predict the company's stock price to reach $19.33 in the next year. This suggests a possible upside of 330.6% from the stock's current price. View analysts price targets for SCPH or view top-rated stocks among Wall Street analysts. How have SCPH shares performed in 2024? scPharmaceuticals' stock was trading at $6.27 on January 1st, 2024. Since then, SCPH shares have decreased by 28.4% and is now trading at $4.49. View the best growth stocks for 2024 here. When is scPharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024. View our SCPH earnings forecast. How were scPharmaceuticals' earnings last quarter? scPharmaceuticals Inc. (NASDAQ:SCPH) announced its quarterly earnings data on Wednesday, March, 13th. The company reported ($0.35) earnings per share for the quarter, topping analysts' consensus estimates of ($0.42) by $0.07. The company earned $6.10 million during the quarter, compared to the consensus estimate of $6.10 million. scPharmaceuticals had a negative trailing twelve-month return on equity of 97.18% and a negative net margin of 403.22%. What other stocks do shareholders of scPharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other scPharmaceuticals investors own include Adamas Pharmaceuticals (ADMS), Dynavax Technologies (DVAX), Fulcrum Therapeutics (FULC), ImmunoGen (IMGN), VBI Vaccines (VBIV), Selecta Biosciences (SELB), SCYNEXIS (SCYX), Syndax Pharmaceuticals (SNDX), Sorrento Therapeutics (SRNE) and TG Therapeutics (TGTX). When did scPharmaceuticals IPO? scPharmaceuticals (SCPH) raised $96 million in an initial public offering on Friday, November 17th 2017. The company issued 6,400,000 shares at a price of $14.00-$16.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO. Who are scPharmaceuticals' major shareholders? scPharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Rice Hall James & Associates LLC (0.78%), Thomasville National Bank (0.10%) and Assenagon Asset Management S.A. (0.05%). Insiders that own company stock include 5Am Partners Iv, Llc, Jack A Khattar, John H Tucker and Orbimed Advisors Llc. View institutional ownership trends. How do I buy shares of scPharmaceuticals? Shares of SCPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:SCPH) was last updated on 4/27/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyHe Is Giving Away BitcoinCrypto Swap ProfitsThe A.I. story nobody is telling you (Read ASAP)TradeSmithFed launches fourth dollar overhaulStansberry ResearchBiden out June 13; Kamala won’t replace him?Paradigm PressMan Who Predicted 2008: “This Will be Worse.”AltimetryJeff Bezos Just Humiliated Elon MuskInvestorPlace Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding scPharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.